Table 5.

Multivariate analysis for RFS at 3 years after alloHCT

Multivariable analysis with variables at diagnosisHRLower CIUpper CIP value
DNMT3A comutation (vs not) 2.64 1.20 5.79 .016 
ICC-defined TP53mut MN (vs does not meet) 1.81 0.95 3.46 .07 
Non-DBD TP53mut only (vs ≥1 DBD mutation) 3.40 1.44 8.06 .005 
CK (vs no CK) 1.14 0.58 2.27 .7 
Multivariable analysis with variables at pre-alloHCT HR Lower CI Upper CI P value 
Cytogenetic response     
CK at diagnosis, but not pre-alloHCT (vs no CK) 1.41 0.67 2.96 .36 
CK pre-alloHCT (vs no CK) 1.72 0.81 3.66 .16 
Melphalan-based conditioning (vs no melphalan) 0.52 0.33 0.82 .005 
PTCy-based GVHD prophylaxis (vs not) 1.25 0.71 2.20 .43 
Pre-alloHCT BM blasts ≥5% (vs <5% blasts) 2.76 1.33 5.34 .006 
Multivariable analysis with variables at diagnosisHRLower CIUpper CIP value
DNMT3A comutation (vs not) 2.64 1.20 5.79 .016 
ICC-defined TP53mut MN (vs does not meet) 1.81 0.95 3.46 .07 
Non-DBD TP53mut only (vs ≥1 DBD mutation) 3.40 1.44 8.06 .005 
CK (vs no CK) 1.14 0.58 2.27 .7 
Multivariable analysis with variables at pre-alloHCT HR Lower CI Upper CI P value 
Cytogenetic response     
CK at diagnosis, but not pre-alloHCT (vs no CK) 1.41 0.67 2.96 .36 
CK pre-alloHCT (vs no CK) 1.72 0.81 3.66 .16 
Melphalan-based conditioning (vs no melphalan) 0.52 0.33 0.82 .005 
PTCy-based GVHD prophylaxis (vs not) 1.25 0.71 2.20 .43 
Pre-alloHCT BM blasts ≥5% (vs <5% blasts) 2.76 1.33 5.34 .006 

Boldface values indicate statistically significant at P < 0.05.

or Create an Account

Close Modal
Close Modal